[{"id":"864e20df-a59c-41cd-b490-615021eb2ec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03545815","created_at":"2021-01-18T17:27:27.742Z","updated_at":"2024-07-02T16:36:42.187Z","phase":"Phase 1","brief_title":"Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.","source_id_and_acronym":"NCT03545815","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC008t • MPTK-CAR-T cells • MSLN CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 03/19/2018","start_date":" 03/19/2018","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2020-08-10"},{"id":"6ec895e3-f79e-43a0-b8a4-dabd649c51b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03747965","created_at":"2021-01-18T18:22:50.032Z","updated_at":"2024-07-02T16:37:05.167Z","phase":"Phase 1","brief_title":"Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors","source_id_and_acronym":"NCT03747965","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • cyclophosphamide • GC008t"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2018-11-20"}]